Analyst Price Target Update on Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA): 3 analysts have set the short term price target of Arena Pharmaceuticals (NASDAQ:ARNA) at $3. The standard deviation of short term price target has been estimated at $1.32, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 4 and $2 respectively.

Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Woods Randall E, director of Arena Pharmaceuticals Inc, had unloaded 76,300 shares at an average price of $4.49 in a transaction dated on March 30, 2015. The total value of the transaction was worth $342,587.

Arena Pharmaceuticals (NASDAQ:ARNA) : On Monday heightened volatility was witnessed in Arena Pharmaceuticals (NASDAQ:ARNA) which led to swings in the share price. The stock opened for trading at $2.02 and hit $2.069 on the upside , eventually ending the session at $2, with a gain of 0.5% or 0.01 points. The heightened volatility saw the trading volume jump to 1,115,663 shares. The 52-week high of the share price is $5.12 and the company has a market cap of $486 million. The 52-week low of the share price is at $1.3 .

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.